Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelizumab combined with dacarbazine and cisplatin for first-line advanced acral melanoma
ChiCTR2400088219Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, dacarbazine and cisplatin in melanoma and acral lentiginous melanoma (ALM), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
adebrelimabdacarbazinecisplatin
03
Conditions
melanomaacral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ChiCTR2400088219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088219.